Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance
Calls on Company to Reach a Fair Settlement that Appoints Altai Nominees
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317768148/en/
In the letter, Altai calls on the OraSure Board to reach a fair settlement that results in the appointment of Altai’s highly-qualified director nominees,
Highlights of the letter, which can be found in full here, include:
- Chronic Underperformance. OraSure’s share price has dramatically underperformed comparable companies and broader indices over both five- and ten-year periods. Recent underperformance has been driven by repeated operational and strategic failures under the current management team—failures that occurred on the Board’s watch. Despite this track record, the Company continues to burn cash pursuing speculative diagnostics investments to the detriment of shareholders.
-
A Board Without Skin in the Game. Independent directors collectively own less than 1% of shares outstanding yet collect over
$250,000 each per year in compensation. They bear little financial risk for decisions that have destroyed shareholder value. Shareholders who face the very real risk of losing money on their investment deserve a larger voice on the Board.
-
Pay Without Performance. Over 90% of CEO Carrie Eglinton Manner’s compensation is not tied to share price performance. She has earned an estimated
$15 million over her tenure while shareholders have lost 60% of their investment since 2023. Her incentives are plainly misaligned with shareholder interests.
-
The Imperative for a Strategic Review.
OraSure must evaluate a sale of the entire business alongside its current plan. We will represent and advocate for all shareholder interests in this process upon our appointment to the Board to ensure that the outcome delivers the best possible returns to shareholders.
-
Nominees With a
Track Record of Results.Rishi Bajaj led ContextLogic’s transformation from a company burning$80 million of cash per quarter to one that completed a$907.5 million acquisition, producing a share price increase of over 120%.John Bertrand built the company behind the first FDA-cleared autonomous AI diagnostic solution in healthcare. Both nominees will seek to align their compensation directly with shareholder returns.
As previously announced, Altai has formally nominated
About
Disclaimers
This press release and the opinions herein are for general information only, and are not intended to be, nor should they be construed as, an offer to sell or a solicitation of an offer to buy any security, a recommendation to purchase or sell any security, or legal, financial, tax, investment, or other advice.
Information about the Participants and a description of their direct or indirect interests, by security holdings or otherwise, is contained in Exhibit 1 to the Schedule 14A filed by the Participants with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20260317768148/en/
Media Contact:
tingraham@ascadvisors.com/ mrayden@ascadvisors.com
Source: